Scholarlink

<p>Benign prostatic hyperplasia (BPH) is a common disorder which affects 25–60% of men throughout their life. The most common BPH medical management consist of finasteride and tamsulosin. Some studies show the increasing risk of metabolic syndrome following BPH drug administration. Thus, we decided to evaluate serum lipid, glucose profile, and oxidative stress markers among BPH patients who received tamsulosin alone and in combination with finasteride. Seventy patients with BPH were referred to lab department to determine their baseline metabolic parameters and serum oxidative/inflammatory markers. Then, randomly divided into two groups including tamsulosin, 0.4 mg daily, orally, and tamsulosin 0.4 mg + finasteride 5&#xa0;mg daily, orally. Following 6&#xa0;months, blood sampling was done again for evaluation of previous markers. Data obtained from before and after the intervention were analyzed and <i>p</i> &lt; 0.05 considered significant level. After 6&#xa0;months of tamsulosin treatment, we demonstrated a significant elevation in fasting blood sugar (FBS), triglyceride (TG), cholesterol, and low-density lipoprotein (LDL). Combination therapy with tamsulosin and finasteride significantly increased serum profile of FBS, TG, cholesterol, and LDL and decreased serum levels of malondialdehyde (MDA), high-density lipoprotein (HDL), glutathione peroxidase (GPx), and ferric reducing antioxidant power (FRAP) after the intervention. This study showed that treating of BPH patients with tamsulosin alone and in combination with finasteride could disturb in serum glucose and lipid profile. Physicians should consider these complications in the follow-up of their patients when prescribed of these drugs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluation of the Effect of Finasteride and Tamsulosin on Glucose, Lipid, and Oxidative Stress Factors of Patients with Benign Prostatic Hyperplasia

  • 期刊论文

  • 发表日期：

    2025年4月10日

查看全文
  • Moslem Sedaghattalab,
  • Ghaidafeh Akbari,
  • Mohammad Malekzadeh,
  • Amirhossein Doustimotlagh,
  • Seyed Mohammadreza Rabani,
  • Saeid Mehrabi

摘要

Benign prostatic hyperplasia (BPH) is a common disorder which affects 25–60% of men throughout their life. The most common BPH medical management consist of finasteride and tamsulosin. Some studies show the increasing risk of metabolic syndrome following BPH drug administration. Thus, we decided to evaluate serum lipid, glucose profile, and oxidative stress markers among BPH patients who received tamsulosin alone and in combination with finasteride. Seventy patients with BPH were referred to lab department to determine their baseline metabolic parameters and serum oxidative/inflammatory markers. Then, randomly divided into two groups including tamsulosin, 0.4 mg daily, orally, and tamsulosin 0.4 mg + finasteride 5 mg daily, orally. Following 6 months, blood sampling was done again for evaluation of previous markers. Data obtained from before and after the intervention were analyzed and p < 0.05 considered significant level. After 6 months of tamsulosin treatment, we demonstrated a significant elevation in fasting blood sugar (FBS), triglyceride (TG), cholesterol, and low-density lipoprotein (LDL). Combination therapy with tamsulosin and finasteride significantly increased serum profile of FBS, TG, cholesterol, and LDL and decreased serum levels of malondialdehyde (MDA), high-density lipoprotein (HDL), glutathione peroxidase (GPx), and ferric reducing antioxidant power (FRAP) after the intervention. This study showed that treating of BPH patients with tamsulosin alone and in combination with finasteride could disturb in serum glucose and lipid profile. Physicians should consider these complications in the follow-up of their patients when prescribed of these drugs.